Epitalon protocol: typical cycles and research doses from the Khavinson literature
Overview of Epitalon research protocols: typical cycle durations, dose ranges from the Khavinson school, stability, and limitations of the current evidence base.
TL;DR: Cycle architecture instead of continuous dosing
Substance: Epitalon (Epithalon, AEDG) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation.
Research protocols: The cycle structure most frequently documented in the Russian literature is 10-20 days at 5-10 mg/day, one to three cycles per year. Continuous dosing is explicitly not the paradigm.
Status: Clinically approved in Russia (sister preparation Epithalamin), in the EU/USA exclusively a research compound without approval.
Epitalon is by far the most-researched longevity peptide in the Khavinson tradition. The evidence base is mixed: over 25 years of primary literature from the St. Petersburg school, several Russian long-term studies, a recent PMC review (2025), and a small but growing number of Western in vitro replications. For research practice, one question above all arises: which protocol structure is documented in the original work?
This article situates the research protocols most frequently used in the literature, without making any clinical recommendations.
Mechanism in brief
Epitalon (AEDG, Ala-Glu-Asp-Gly) is a tetrapeptide derived from sequence analysis of the pineal gland extract Epithalamin. The central mechanistic hypothesis from the Khavinson work:
- DNA binding: AEDG binds selectively to specific promoter regions, including sequences in the telomerase region
- Telomerase activation: In vitro, an upregulation of telomerase activity and telomere elongation in somatic cells was observed in Khavinson replications
- Melatonin axis: restoration of age-related declining melatonin secretion in several animal models and in a human pilot study in elderly subjects
- Pleiotropic effects: documented in animal and cell models for immune function, antioxidant markers, and circadian regulation
Current review source
The most comprehensive recent review on the bioactivity of Epitalon is the open-access paper from 2025 in PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/. It consolidates 25 years of primary literature and is the recommended entry source for study designs.
Tetrapeptide (Ala-Glu-Asp-Gly) that activates telomerase, the enzyme responsible for maintaining telomere length. One of the most studied peptides in longevity research, developed by Prof. Khavinson at the St. Petersburg Institute of Bioregulation.
Typical research doses and cycle structure
The protocols most frequently cited in the primary literature follow a cycle concept, not continuous dosing. The background: Khavinson and colleagues argue that the regulatory action of bioregulators is intermittent rather than permanent; the pause between cycles is part of the mechanism concept.
Cycle duration: 10 to 20 days
The standard cycles documented in the Khavinson literature are 10 days (short variant) or 20 days (standard variant). Longer uninterrupted dosing is not described in the primary sources.
Dose per day: 5 to 10 mg
The typical daily research dose ranges between 5 and 10 mg. Some sources mention a single daily dose, others a split into two doses (morning, evening). The precise rationale for the split is rarely discussed systematically in the literature.
Repetition: 1 to 3 cycles per year
As standard, the Khavinson school conducts one cycle per year; some protocols use seasonal repetitions (e.g. spring and autumn). More than three cycles per year are not substantiated in the primary literature.
Pauses between cycles
Between two cycles there is typically a pause of several months. This is a defining characteristic of the bioregulator paradigm, not a safety workaround.
What the dose figures are not
The figures cited here are observations from research and animal-experimental protocols, not dosing recommendations. A broad, peer-reviewed dose-response analysis to Western standards (placebo-controlled, double-blind, with adequate sample sizes) does not exist for Epitalon. Anyone working with these protocols in preclinical models should consult the respective primary source directly.
Reconstitution and stability
Lyophilised Epitalon is stable at -20 °C in the original packaging. Before reconstitution, the vial should reach room temperature to avoid condensation.
Add bacteriostatic water
Introduce the desired volume of bacteriostatic water slowly along the inner wall of the vial, not directly onto the lyo cake. Example: 2 ml BAC water on 10 mg Epitalon yields a concentration of 5 mg/ml.
Let it dissolve
Do not shake the vial; let it rest for a few minutes. With residual particles, gently roll it between the fingers.
Store cool and dark
Store the reconstituted solution at 2-8 °C, protected from light. Avoid repeated freeze-thaw cycles, as they can compromise the integrity of small peptides.
Label immediately
Write the peptide name, concentration, diluent, and reconstitution date on the vial. Unlabelled vials in a shared refrigerator lead to mix-ups.
USP-grade sterile water with 0.9% benzyl alcohol - the standard solvent for reconstituting lyophilized peptides. Essential accessory for any peptide research. Each vial is sealed and ready to use.
Limitations of the current evidence
Anyone using Epitalon in research designs should be aware of the limits of the published evidence base:
- Geographic concentration of the primary literature: more than 80% of published work originates from the Khavinson group in St. Petersburg. Independent Western replications are rare and mostly confined to in vitro models.
- Methodological heterogeneity: study protocols vary in dose, cycle duration, animal model, and endpoint. A central meta-analysis is lacking.
- Telomerase hypothesis in humans: evidence from human in vitro models exists (see PMC PMC12411320, 2025), yet in vivo telomere elongation in humans is not substantiated by sufficiently large, controlled studies.
- Regulatory status: no FDA or EMA approval. In Russia, the related preparation Epithalamin is clinically approved.
Source recommendation for study planning
Start with the 2025 PMC review (PMC11943447) for the mechanistic framing. For protocol-specific details, the original work by Khavinson and Anisimov in the Bulletin of Experimental Biology and Medicine is the central source. For human telomere data, see Khavinson et al., Bull Exp Biol Med 2003.
Cluster context: longevity stack
In longevity research, Epitalon is frequently discussed in the context of other bioregulators and mitochondrially active peptides. Two candidates available in our catalogue for complementary stack designs:
Skin regeneration / copper peptide
Sourcing and quality
Buy Epitalon at Peptides Direct: every batch is independently tested by Janoshik Analytical via HPLC for identity and purity (≥98%). The certificate of analysis is viewable on the product page, batch-specific.
Sources
- Khavinson V et al. Overview of Epitalon - Highly Bioactive Pineal Tetrapeptide with Promising Properties. PMC, 2025: https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/
- Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. PMC, 2025: https://pmc.ncbi.nlm.nih.gov/articles/PMC12411320/
- Khavinson V, Bondarev I, Butyugov A. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med, 2003;135(6):590-2.
- Anisimov VN, Khavinson VK et al. Effect of synthetic peptides Epitalon and Vilon on the lifespan of mice. multiple Bull Exp Biol Med papers 2001-2008.
This article is intended for information purposes for scientific research only.
Disclaimer: FOR RESEARCH USE ONLY. All products from Peptides Direct are intended exclusively for in vitro research and laboratory use. Not for human consumption. Not for in vivo applications. By purchasing, you confirm that the products are not intended for ingestion or any other application in humans.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include 19% VAT; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.